Will McDonough et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 34(9), 12533-12548 (2020-08-02)
Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promising therapeutic benefits, but adverse effects, in particular emesis and nausea, have curbed their clinical utility. Here, we show that PAN-selective inhibition of PDE4, but not inhibition of PDE3, causes a